Treatment of acute myeloid leukemia (AML): Recent results and new directions
Abstract
#No Abstract#
Hann IM., Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as in- duction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML Trial (MRC AML10). Blood 1997;89:2311-8
Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autolo- gous bone-marrow transplantation to intensive chemotherapy of acute myeloid leukaemia in first re- mission: results of MRC AML10 trial. The Lancet 1998;351:700-8
Mandelli F, Vegna ML, Avvisati G, et al. A randomized study of the efficacy of postconsolida- tion therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GI- MEMA. Annals of Hematology 1992;64:166-72
Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remis- sion. New England Journal of Medicine 1998;339:1649-56
Rai KR, Hollannd JF, Glidewell OJ, et al. Treatment of acute myeloid leukemia: A study by Can- cer and Leukemia Group B. Blood 1981;58:1203-12
Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982;60:454-62
Büchner T, Urbanitz D, Hiddemann W, et al. Intensified Induction and Consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. Journal of Clinical Oncology 1985;3:1583-9
Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Principal results of the Medical Research Coun- cil’s 8th acute myeloid leukaemia trial. The Lancet 1986;332:1236
Hayat M, Jehn U, Willemze R, et al. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. Cancer 1986;58:617-23
Zittoun R, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995;332:217-223
Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leu- kemia Group B Study. Blood 1987;69:1441-9
Hansen OP, Pedersen- Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside ver- sus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leuke- mia: a Danish National Phase III Trial. Leukemia 1991;5:510-6
Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytara- bine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 1991;78:2520-6
Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute mye- loid leukemia. Blood 1992;79:1924-30
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine 1994;6:896-942
Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induc- tion in acute myeloid leukemia. Blood 1996;87:1710-7
Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute mye- loid leukemia: A Southwest Oncology Study Group. Blood 1996;88:2841-51
Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leu- kemia: The effect of high-dose cytarabine with mitoxantrone instead of standard- dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-24
Büchner T, Hiddemann W, Berdel W, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de- novo acute myeloid leukemia (AML): A randomized trial by the German AML Cooperative Group. Journal of Clinical Oncology 2003;21:4496-4504
Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony- stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. New England Journal of Medicine 2003;349:743-752
Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo- controlled phase III study of granulocyte-macrophage colony- stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-62
Witz F, Sadoun A, Perrin MC, et al. A placebo- controlled study of recombinant human granulo- cyte-macrophage colony- stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998;91:2722-30
Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Coun- cil AML 11 trial. Blood 2001;98:1302-11
Anderson J, Kopecky K, Willmann C, et al. Outcome after induction chemotherapy for older pa- tients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cyta- rabine and daunorubicin: A Southwest Oncology Group study. Blood 2002;100:3869-3876
Stone RM, Berg TB, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine 1995;332:1671-7
Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001;98:548-53
Büchner T, Hiddemann W, Wörmann B, et al. Daunorubicin 60 instead of 30 mg/sqm improves response and survival in elderly patients with AML. Blood 1997:90 (Suppl 1):583a
Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New Eng- land Journal of Medicine 1995;332:1678-83
Rees JKH, Gray RG, Weathley K. Dose intensification in acute myeloid leukaemia: greater effec- tiveness at lower cost. Principal report of the Medical Research Council’s AML9 study. British Journal of Haematology 1996;94:89-98
Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990;75:27-32
Löwenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction- consolidation chemotherapy – The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the Leukemia Cooperative Group of the European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group randomized phase III study AML-9. Journal of Clinical Oncology 1998;16:872-81
Rowe J, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485
Büchner T, Berdel WE, Wörmann B, et al. Treatment of older patients with AML. Critical Re- views in Oncology/ Hematology 2005 (in press)
Huang M, Ye Y, Chen S, et al. Use of all- trans retinoic acid in the treatment of acute promyelo- cytic leukemia. Blood 1988; 72:567-572
Avvisati G, Lo Coco F, Diverio D, et al. AIDA ( All-trans Retinoic Acid + Idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne Dell’ Adulto (GIMEMA) pilot study. Blood 1996;88:1390-1398
Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline- based con- solidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR α- positive acute promyelocytic leukemia. Blood 1999;94:3015-3021
Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytara- bine in combination with all- trans retinoic acid: effects in patients with newly diagnosed acute pro- myelocytic leukemia. Leukemia 2000; 14:1362-1370
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As203) in the treatment of acute pro- myelocytic leukemia (APL). II Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1992;79:543-553
Gavamzadeh A, Alimoghaddam, K, Aghdami, N, Treatment of acute promyelocytic leukemia by arsenic trioxide. Proc. ASCO 2003;22:568
Shen ZX, Shi ZZ, Fang J, All- trans retinoic acid/As2O3 combination yields a high quality remis- sion and survival in newly diagnosed acute promyelocytic leukemia. PNAS 2004;101:5328-5335
Mesters R, Padró T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001;98:241-243
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of Gemtuzumab Ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology 2001;19:3244-3254
Nabhan C, Rundhaugen LM, Riley MB, et al. Phase III pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leukemia Research 2005; 29:53-57
Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Can- cer and Leukemia Group B study 9720. Blood 2002;100:1224-1232
Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia Group B study 9621. Journal of Clinical Oncology 2004;22:4290-4301
Büchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony stimulating factor- rela- tion to high- dose cytarabine in acute myeloid leukemia. New England Journal of Medicine 2004;350:2215-16 (letter)
Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplan- tation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to- treat analysis of the EORTC/GIMEMA AML-10 trial. Blood 2003;102:1232-1240
| Files | ||
| Issue | Vol 1, No 2 (2004) | |
| Section | Articles | |
| Keywords | ||
| #No Keywords# | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
